Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Virchows Archiv : an International Journal of Pathology|July 2, 2020
The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlationHans Bösmüller, Selina Traxler, Michael Bitzer, et al.
Virchows Archiv : an International Journal of Pathology|August 23, 2023
Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle studyDominik Nann, Achim Rau, Lejla Mahmutovic, et al.
Experimental and Therapeutic Medicine|October 19, 2023
Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case reportElena Stingu, Jerome-Maurice Dobrowolski, Paula Bombach, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 21, 2020
Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapyFranz J Hilke, Francesc Muyas, Jakob Admard, et al.
Endocrine-Related Cancer|October 5, 2016
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumorsSimona Falletta, Stefano Partelli, Corrado Rubini, et al.
The Journal of Pathology. Clinical Research|September 4, 2025
Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesisDominik Nann, Tim-Colin Schade, Mathis Overkamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2018
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal CarcinomatosisUlrich M Lauer, Martina Schell, Julia Beil, et al.
Frontiers in Oncology|April 22, 2025
Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusionNadja Ballin, Alexander Ott, Olga Seibel-Kelemen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 27, 2020
PET/MRI and genetic intrapatient heterogeneity in head and neck cancersKerstin Clasen, Sara Leibfarth, Franz J Hilke, et al.
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.
Pageof 3